Riluzole 50, 100, 200 mg/ dag eller placebo, og de blev fulgt i 18 måneder.
In a dose-ranging trial, 959 patients with ALS were randomised to one of four treatment groups: riluzole 50, 100, 200 mg/ day, or placebo and were followed-up for 18 months.